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PD: A neurodegenerative movement disease. 
Prevalence: Affects up to 2% of individuals over 60. 
Risk factors: Age. 
Diagnosis: Clinical & neuropsychological assessment 
Symptoms:   Motor:  tremor, slow movement, rigidity; 
                      Cognitive: impairments in multiple domains, including attention, executive,  
 function, and memory; 
                      Others:  sleep disturbance and swallowing difficulties. 
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Table 2. The brain metabolites and their physiological significance.  
Metabolite Physiological Significance Interpretation  
N-Acetylaspartate (NAA) Neuronal integrity marker Reduced NAA indicates compromised 
neuronal integrity  
Choline  (Cho) Cell membrane breakdown marker Increased Cho indicates higher cell 
membrane breakdown 
Creatine  (Cr) Represents energy storage  Relatively stable in most diseases 
myo-Inositol  (mI) Glial cell marker Increased mI indicates an ongoing gliosis  
Controls  PDN PDMCI PDD 
n  49 77 33 20 
Sex (M/F) 33/16 51/26 21/12 17/3 
Age (years) 68(8) 64(8)* 70(5)  73(7)* 
Education (years) 13(2) 13(2) 13(3) 12(2) 
Disease duration(years) NA 2(3) 5(5) 10(8) 
LED (mg/day) NA 221(333) 403(428) 736(400) 
Cognitive Z score 0.63(0.37) 0.26(0.43)** -0.72(0.39)** -1.71(0.58)** 
MoCA 27(1.9) 26(2.2)** 27(2.4)** 17(3.8)** 
Table 1.  Demographic and neuropsychological data by group at baseline 
Values are mean (sd). *p<0.05 & **p<0.001 between control and PD groups at baseline. LED = Levodopa 
Equivalent Dose. MoCA = Montreal Cognitive Assessment. Z score = represents the global cognition.   
Table 3.  Baseline and follow-up results of cognitive performance and MRS markers 
For baseline: values are mean difference estimates for PDN, PDMCI and PDD relative to controls.  
For follow-up: values are mean difference estimates representing the annual rate of change for PDN and PDMCI relative to 
controls. Values with negative signs represent the decrease in either the global cognitive score or MRS measures over time. 
95% PI = 95% Probability Interval. *Significantly different relative to healthy controls.  
  
Figure 2. Trajectory of global cognitive Z score over time by cognitive group (top) and 










As the disease progresses, cognitive impairments become more manifest in many patients, ultimately 
leading to dementia in the majority. However, there is considerable variation (range 2-20 years) 
between onset of the initial motor disorder and the emergence of dementia.1 Importantly, this delay 
provides a window for potential therapeutic intervention.  
Detecting cognitive impairment at its earliest stages would facilitate the most appropriate and timely 
intervention aimed at slowing the progression to dementia. 
However, the assessment of neuroprotective and disease-modifying therapies in PD has been 
hampered by a lack of clinically useful, reliable neurobiomarkers.  
 








Magnetic Resonance Spectroscopy (MRS) provides an attractive option to identify a 












To examine whether MRS of posterior cingulate cortex (PCC) can track the metabolic changes 






• All subjects completed a neuropsychological battery and were classified as healthy controls (HC), PD with normal cognition 
(PDN), PD with mild cognitive impairment (PDMCI), or PD with dementia (PDD) (Table 1). 
• At baseline, 179 subjects underwent MR spectroscopy examinations. 
• The follow-up stage involved re-imaging 173 controls and non-demented subjects for up to 4 years after their initial 
assessment. 
• 2 × 2 × 3cm3 MRS voxel was placed on the posterior cingulate cortex of the brain (Figure 1). 












• Cognition performance scores significantly varied at baseline and over time among the groups. 
• MRS markers showed no significant group difference at baseline. 
• At follow-up, neither a significant change in MRS markers nor a relationship between the MRS 
markers and the change in the cognitive status were identified (Table 3). 
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• With a large sample size and comprehensive neuropsychological assessment, we were unable to 
identify any significant change in MRS parameters relating to cognitive status at baseline or over 
time.  
• Our findings suggest that MRS, of the PCC at least, is not a clinically useful biomarker of 









Figure 1. Axial, coronal, and sagittal (left to right) MRI structural images showing the 




 (95% PI) 
PDN – HC 
 (95% PI ) 
PDMCI – HC 
 (95% PI ) 
PDD – HC 
 (95% PI ) 
  Cognitive Z score 0.53 
(0.37 — 0.70) 
-0.32* 
(-0.48 — -0.16) 
-1.23* 
(-1.42 — -1.03) 
-1.53* 
(-2.33 — -0.60) 
NAA/Cr 1.64 
(1.52 — 1.76) 
0.013 
(-0.06 — 0.08) 
0.002 
(-0.07 — 0.07) 
-0.248 
(-0.53 — 0.01) 
Cho/Cr 0.50 
(0.45 — 0.56) 
0.01 
(-0.02 — 0.04) 
0.01 
(-0.02 — 0.05) 
0.08 
(-0.056 — 0.21) 
            
Follow-up change   HC unit/year 
(95% PI) 
PDN unit/year – HC 
(95% PI) 




Cognitive Z score 0.007 
( -0.0368 — 0.0510) 
-0.068* 
( -0.1278 — -0.0058) 
-0.141* 
( -0.2296 — -0.0410) 
  
NAA/Cr -0.013 
(-0.0333 — 0.0064) 
-0.008 
(-0.0265 — 0.0108) 
-0.003 
(-0.0292 — 0.0216) 
  
Cho/Cr 0.002 
(-0.0059 — 0.0101) 
0.004 
(-0.0045 — 0.0122) 
-0.004 
(-0.0157— 0.0072) 
  
